Visual Overview
Pipeline Chart
Our pipeline includes innovative therapies targeting moderate-to-severe psoriasis, atopic dermatitis, psoriatic arthritis, and chronic autoimmune inflammatory diseases.
AlsysLife's therapeutic candidates are at various stages of development, with two ongoing international registrational trials targeting psoriasis and related autoimmune conditions.
Our leading candidates combine natural product science with structure-based drug design to deliver novel mechanisms of action.
A first-in-class natural product-derived therapy targeting S100 proteins and key inflammatory signaling pathways. PRC0028 has demonstrated significant efficacy in completed and ongoing international registrational trials for plaque psoriasis.
A next-generation antimicrobial peptide inhibitor designed to target the AMP signaling axis implicated in chronic autoimmune inflammatory disease. BA01 represents AlsysLife's novel approach to modulating innate immunity in skin disorders.